AUG 20, 2014 06:00 AM PDT

The realization of the promise of personalized molecular medicine requires efficient development and implementation of novel targeted therapeutics lin

  • Department Chair, Department of Systems Biology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center

      Gordon B. Mills, MD, PhD, was recruited to The University of Texas M. D. Anderson Cancer Center in 1994, where he holds the rank of Professor with joint appointments in Systems Biology, Breast Medical Oncology and Immunology; serves as chairman of the Department of Systems Biology; head of the section of Molecular Therapeutics and holds the Wiess Distinguished University Chair in Cancer Medicine. Dr. Mills is co-Director of the Kleberg Center for Molecular Markers and Director for the Gita and Ali Saberioon Molecular Markers building. This Center is responsible for developing personalized molecular medicine at MDACC. Dr. Mills has published extensively on the molecular analysis of cancer and currently serves as principal investigator or project investigator on many national peer review grants including NIH/NCI SPOREs and PPGs, Department of Defense, and Komen Foundation grants, and is a collaborator on multiple other national grants. Dr. Mills also holds more than 20 patents related to novel technologies and molecular markers and has co-founded an early diagnostics company. He currently sits on the scientific advisory boards of multiple companies and venture capital groups. Based on his expertise in technology development, he is the head of the M. D. Anderson Cancer Center Technology Review Committee.


    Show Resources
    Loading Comments...